

Regd. Office :-
330, TRIVIA Complex, Natubhai Circle,
Racecourse, Vadodara – 390007, Gujarat, INDIA
Phone : +91 265 2988903 / 2984803
Website : www.chemcrux.com
Email : girishshah@chemcrux.com



**CHEMCRUX**
ENTERPRISES LTD.
ISO 9001, 14001 & 50001 Certified Company
CIN : L01110GJ1996PLC029329

To

05th February 2026

BSE LIMITED

Department of Corporate Services
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400 001

Dear Sir/Madam

Subject: Unaudited Financial Results for the quarter and nine months ended 31st December 2025

Ref.: BSE Scrip ID: CHEMCRUX **BSE Scrip Code:** 540395

We would like to inform that the Board of Directors in its meeting held today i.e., 05th February 2026 inter alia, considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December 2025 as recommended by the Audit Committee.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

1. Limited Review Report issued by the Statutory Auditors of the Company.
2. Statement showing the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December 2025.

Kindly take above as compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 11:30 A.M. and concluded at 01:35 P.M.

Thanking you

For CHEMCRUX ENTERPRISES LIMITED

Dipika Rajpal
Company Secretary & Compliance Officer

Factory

4712-14, GIDC, Road South - 10, Ankleshwar - 393002 (Gujarat) India.
Ph.: +91 2646 221427, 239737 | Email : sanjay@chemcrux.com

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT

To,
The Board of Directors,
Chemcrux Enterprises Limited,


We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Chemcrux Enterprises Limited** ('the Company') for the **quarter and nine months ended 31st December 2025** ('the Statement') attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Listing Regulations')

This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors has been prepared in accordance with recognition and measurement principles laid down in IND AS 34 "Interim Financial Reporting" as prescribed u/s. 133 of the Companies Act, 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review of the Financial Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free from material misstatement. A review is limited primarily to inquiries of Company Personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable Indian Accounting Standards (Ind AS) specified under section 133 of the Companies Act, 2013, together with the Notes thereon and read with relevant rules and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Naresh & Co.
Chartered Accountants
FRN: 106928W


CA Harin Parikh
Partner

M.No. 107606
UDIN: 26107606GRZIRI3844
Place: Vadodara
Date: 05th February, 2026



CHEMCRUX ENTERPRISES LIMITED

CIN : L01110GJ1996PLC029329

Reg. Office : 330, TRIVIA Complex, Natubhai Circle, Race Course, Vadodara - 390007

UNAUDITED STANDALONE STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER 2025

(All amounts are in INR lacs, unless otherwise stated)

	Particulars	Quarter Ended			Period Ended		Year ended
		31-12-2025 Unaudited	30-09-2025 Unaudited	31-12-2024 Unaudited	31-12-2025 Unaudited	31-12-2024 Unaudited	31-03-2025 Audited
I.	Revenue from operations	2,299.74	1,855.31	1,942.36	5,829.78	5,428.83	7,025.39
II.	Other income	74.04	79.81	60.55	214.55	125.22	152.96
III.	Total Income (I+II)	2,373.77	1,935.12	2,002.91	6,044.33	5,554.06	7,178.35
IV.	Expenses:						
	Cost of materials consumed	1,057.60	757.66	869.45	2,367.98	2,308.88	3,042.21
	Purchase of Traded Goods						
	Changes in inventories of finished goods, by-products and work in progress	(118.40)	188.58	(60.10)	395.97	(48.62)	(236.26)
	Employee benefits expense	246.05	211.23	217.48	659.27	634.09	852.68
	Finance costs	45.61	52.02	59.60	150.05	105.55	163.84
	Depreciation and amortization expense	95.34	96.26	92.09	286.26	221.59	313.06
	Other expenses	778.74	531.10	646.08	1,744.63	1,822.54	2,460.01
	Total expenses (IV)	2,104.93	1,836.85	1,824.61	5,604.17	5,044.04	6,595.54
V.	Profit Before Tax	268.84	98.27	178.30	440.17	510.02	582.81
VIII.	Tax expense :						
	Current tax	49.50	8.20	27.04	59.12	72.34	75.00
	Deferred tax	14.74	10.12	19.59	38.05	67.44	90.06
	Income tax relating to earlier years	(3.30)		(1.17)	(3.30)	(1.17)	(1.11)
		60.94	18.32	45.46	93.87	138.61	163.96
IX.	Profit for the period	207.90	79.95	132.84	346.30	371.41	418.86
X	Other comprehensive income						
	(i) Items that will not be reclassified to profit or loss						
	- Defined Benefit Plan	2.40	(0.58)	3.47	(11.25)	7.30	26.18
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.60	(0.15)	0.87	(2.83)	1.84	6.59
	(iii) Items that will be reclassified to profit or loss						
	-Fair Value Gain on Investments	23.75	26.56	11.85	90.52	87.01	126.92
	(iv) Income tax relating to items that will be reclassified to profit or loss	5.98	6.68	2.98	22.78	21.90	31.95
	Total other comprehensive income, net of tax	19.56	19.44	11.46	59.32	70.57	114.57
XI.	Total comprehensive income for the period	227.46	99.39	144.30	405.62	441.98	533.42
	Paid Up Equity Share Capital (face value of Rs. 10/- each)						1,480.88
	Other Equity						5,981.37
XII.	Earnings per equity share (Nominal value per share Rs. 10/-)						
	- Basic (Rs.)	1.40	0.54	0.90	2.34	2.51	2.83
	- Diluted (Rs.)	1.40	0.54	0.90	2.34	2.51	2.83



[Handwritten signature]


Notes to Standalone Financial Results :

- 1 The above financial results have been prepared in accordance with Indian Accounting Standards as prescribed under Section 133 of the Companies Act 2013 read with the Companies (Indian Accounting Standards) Rules as amended from time to time and other relevant provisions of the Act.
- 2 The above financial results have been reviewed by the Audit Committee and Approved by the Board of Directors in their respective Meetings held on 05th February, 2026.
- 3 The Company is primarily engaged in the business of manufacturing and processing of Bulk Drug Intermediates, which in terms of ind AS 108, on Operating Segment, constitute a single operating segment.
- 4 The Government of India has consolidated 29 existing labour legislation into a unified framework comprising four labour codes viz the Code on Wages, 2019, the Code on Social Security, the Industrial Relation Code, 2020 and the Occupational Safety, Health and Working Condition Code, 2020 (collectively referred to as the "Codes"). The Codes have been made effective from November 21, 2025. Te Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations.

The Company has assessed the impact of these changes based on the information currently available and consistent with the guidance provided by the Institute of Chartered Accountants of India. Based on this assessment, there is no impact on the standalone financial results for the quarter and nine months ended December 31, 2025, and consequently, no adjustments have been made. Once the Central/State Rules are notified by the Government on all aspects of the Codes, the Company will re-evaluate the impact, if any, on the measurement of employee benefits and provide appropriate accounting treatment.

- 5 The figures of the corresponding previous periods have been regrouped/reclassified wherever considered necessary to confirm to the figures represented in the current period.

**For & on behalf of the Board
Chemcrux Enterprises Limited**


Girishkumar Shah
Whole Time Director
DIN : 00469291



Place : Vadodara
Date : 05th February, 2026

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON CONSOLIDATED FINANCIAL RESULTS

To,
The Board of Directors,
Chemcrux Enterprises Limited,

We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Chemcrux Enterprises Limited** ('the Holding Company') and its Subsidiary ('Kalichem Private Limited') (the Holding Company and its Subsidiary together referred to as 'the Group') for the **quarter and nine months ended 31st December 2025**, read together with the Notes thereon ('the Statement'), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('Listing Regulations') as amended.

This Statement, which is the responsibility of the Holding Company's Management and has been approved by the Holding Company's Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in IND AS 34 "Interim Financial Reporting" as prescribed u/s. 133 of the Companies Act, 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these Statement based on our review.

We conducted our review of the Financial Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free from material misstatement. A review is limited primarily to inquiries of Company Personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable

The Statement includes the results of M/s. Kalichem Private Limited (Subsidiary)

Based on our review conducted and procedures performed as stated above, including the limited review of the unaudited financial results of the subsidiary company performed by us, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Indian Accounting Standards (Ind AS) specified under section 133 of the Companies Act, 2013, read with relevant rules and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Other Matters

- a) The Holding Company initially held 50% stake in Kalichem Private Limited making it a Joint Venture. The Holding Company acquired balance 50% stake in Kalichem Private Limited from the co-venturer M/s. Kalintis Healthcare Private Limited on 27th February, 2025. As a result of the acquisition, Kalichem Private Limited became a wholly-owned subsidiary of the Holding Company from that date.


Consequently, the Company has Consolidated the Financial Results of Kalichem Private Limited as a Joint Venture under the Equity Method in accordance with Ind AS 28 till 27th February, 2025 i.e. the date on which Kalichem Private Limited became a wholly-owned subsidiary. For the subsequent period, i.e. from 27th February, 2025 to 31st March, 2025 & the quarterly periods thereafter the Consolidation has been done as a Wholly Owned Subsidiary under Ind AS 110 following the principles of Ind AS 103 Business Combinations.

The consolidated figures relating to the various periods appearing in the Statement are in accordance with the above.

- b) The Statement includes the figures relating to quarter and nine month ended 31st December, 2024 for which the financial results of M/s. Kalichem Private Limited were reviewed by other auditors whose review reports have been furnished to us. At that time M/s. Kalichem Private Limited was a Joint Venture and Consolidated under the Equity Method. Our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of Kalichem Private Limited for the quarter and nine months ended 31st December, 2024 is based solely on the report of the other auditor and the procedures performed by us as stated above.

Our Conclusion on the Statement is not modified in respect of the above Other Matters.

For Naresh & Co
Chartered Accountants
FRN: 106928W


CA Harin Parikh
Partner

M.No. 107606

UDIN: 26107606IOASPM4614

Place: Vadodara

Date: 05th February, 2026



CHEMCRUX ENTERPRISES LIMITED

CIN : L01110GJ1996PLC029329

Reg. Office : 330, TRIVIA Complex, Natubhai Circle, Race Course, Vadodara - 390007

UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31ST DECEMBER 2025

(All amounts are in INR Lacs, Unless otherwise stated)

	Particulars	Quarter Ended			Period Ended		Year ended
		31-12-2025 Unaudited	30-09-2025 Unaudited	31-12-2024 Unaudited	31-12-2025 Unaudited	31-12-2024 Unaudited	31-03-2025 Audited
I.	Revenue from operations	2,211.46	1,774.63	1,942.36	5,636.45	5,428.83	7,000.99
II.	Other income	60.23	62.50	60.55	166.80	125.22	148.74
III.	Total Income (I+II)	2,271.70	1,837.13	2,002.91	5,803.25	5,554.06	7,149.73
IV.	Expenses:						
	Cost of materials consumed	839.47	623.03	869.45	1,934.52	2,308.88	2,978.53
	Purchase of Traded Goods						
	Changes in inventories of finished goods, by-products and work in progress	86.03	156.20	(60.10)	395.97	(48.62)	(236.26)
	Employee benefits expense	261.91	225.10	217.48	700.12	634.09	856.44
	Finance costs	76.14	82.60	59.60	244.55	105.55	174.55
	Depreciation and amortization expense	118.68	119.57	92.09	355.94	221.59	320.56
	Other expenses	843.01	591.01	646.08	1,910.92	1,822.54	2,479.38
V.	Total expenses (IV)	2,053.18	1,797.52	1,824.61	5,542.03	5,044.04	6,573.19
VI.	Profit Before Share in profit of Joint Venture (III-IV)	218.52	39.61	178.30	261.22	510.02	576.54
VII.	Share in Profit/(Loss) of Joint Venture (Net of Tax)	-	-	(0.50)	-	(0.50)	(0.50)
VIII.	Profit Before Tax	218.52	39.61	177.80	261.22	509.52	576.04
IX.	Tax expense :						
	Current tax	49.50	8.20	27.04	59.12	72.34	75.00
	Deferred tax	14.74	10.12	19.59	17.27	67.44	110.85
	Income tax relating to earlier years	(3.30)	-	(1.17)	(3.30)	(1.17)	(1.11)
		60.94	18.32	45.46	73.09	138.61	184.74
X.	Profit for the period	157.58	21.29	132.34	188.13	370.91	391.30
XI.	Other comprehensive income						
	(i) Items that will not be reclassified to profit or loss						
	- Defined Benefit Plan	2.40	(0.58)	3.47	(11.25)	7.30	26.18
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.60	(0.15)	0.87	(2.83)	1.84	6.59
	(iii) Items that will be reclassified to profit or loss						
	-Fair Value Gain on Investments	23.75	26.56	11.85	90.52	87.01	126.92
	(iv) Income tax relating to items that will be reclassified to profit or loss	5.98	6.68	2.98	22.78	21.90	31.95
	Total other comprehensive income, net of tax	19.56	19.44	11.46	59.32	70.57	114.57
XII.	Total comprehensive income for the period	177.14	40.73	143.80	247.45	441.48	505.87
	Profit for the period/year attributable to:						
	Owners of the Company	157.58	21.29	132.34	188.13	370.91	391.30
	Other comprehensive income for the period/year attributable to:						
	Owners of the Company	19.56	19.44	11.46	59.32	70.57	114.57
	Total comprehensive income for the period attributable to:						
	Owners of the Company	177.14	40.73	143.80	247.45	441.48	505.87
	Paid Up Equity Share Capital (face value of Rs. 10/- each)						1,480.88
	Other Equity						5,981.37
XIII.	Earnings per equity share (Nominal value per share Rs. 10/-)						
	- Basic (Rs.)	1.06	0.14	0.89	1.27	2.50	2.64
	- Diluted (Rs.)	1.06	0.14	0.89	1.27	2.50	2.64



Notes to Consolidated Financial Results :

- 1 List of Entities Consolidated included in the

Kalichem Private Limited

Joint Venture till 26.02.2025


Wholly-Owned Subsidiary from 27.02.2025

- 2 The above consolidated financial results have been prepared in accordance with Indian Accounting Standards as prescribed under Section 133 of the Companies Act 2013 read with the Companies (Indian Accounting Standards) Rules as amended from time to time and other relevant provisions of the Act.
- 3 The above consolidated financial results have been reviewed by the Audit Committee and Approved by the Board of Directors in their respective Meetings held on 05th February, 2026
- 4 The Holding Company is primarily engaged in the business of manufacturing and processing of Bulk Drug Intermediates, which in terms of in AS 108, on Operating Segment, constitute a single operating segment.
- 5 The Government of India has consolidated 29 existing labour legislation into a unified framework comprising four labour codes viz the Code on Wages, 2019, the Code on Social Security, the Industrial Relation Code, 2020 and the Occupational Safety, Health and Working Condition Code, 2020 (collectively referred to as the "Codes"). The Codes have been made effective from November 21, 2025. Te Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations.

The Company has assessed the impact of these changes based on the information currently available and consistent with the guidance provided by the Institute of Chartered Accountants of India. Based on this assessment, there is no impact on the consolidated financial results for the quarter and nine months ended December 31, 2025, and consequently, no adjustments have been made. Once the Central/State Rules are notified by the Government on all aspects of the Codes, the Company will re-evaluate the impact, if any, on the measurement of employee benefits and provide appropriate accounting treatment.

- 6 The figures of the corresponding previous periods have been regrouped/reclassified wherever considered necessary to confirm to the figures represented in the current period.

**For & on behalf of the Board
Chemcrux Enterprises Limited**


Girishkumar Shah
Whole Time Director
DIN : 00469291



Place : Vadodara
Date : 05th February, 2026